CERo Cash Per Share from 2010 to 2025

CEROW Stock   0.02  0  28.57%   
CERo Therapeutics Cash Per Share yearly trend continues to be fairly stable with very little volatility. Cash Per Share is likely to outpace its year average in 2025. During the period from 2010 to 2025, CERo Therapeutics Cash Per Share regression line of quarterly data had mean square error of  2.03 and geometric mean of  0.12. View All Fundamentals
 
Cash Per Share  
First Reported
2010-12-31
Previous Quarter
1.18
Current Value
2.02
Quarterly Volatility
1.59107936
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check CERo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CERo Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 121.5 K, Interest Income of 121.5 K or Depreciation And Amortization of 2.5 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. CERo financial statements analysis is a perfect complement when working with CERo Therapeutics Valuation or Volatility modules.
  
Check out the analysis of CERo Therapeutics Correlation against competitors.

Latest CERo Therapeutics' Cash Per Share Growth Pattern

Below is the plot of the Cash Per Share of CERo Therapeutics Holdings over the last few years. It is CERo Therapeutics' Cash Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CERo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.00 X10 Years Trend
Slightly volatile
   Cash Per Share   
       Timeline  

CERo Cash Per Share Regression Statistics

Arithmetic Mean0.71
Geometric Mean0.12
Coefficient Of Variation225.17
Mean Deviation0.99
Median0.05
Standard Deviation1.59
Sample Variance2.53
Range6.1774
R-Value0.50
Mean Square Error2.03
R-Squared0.25
Significance0.05
Slope0.17
Total Sum of Squares37.97

CERo Cash Per Share History

2025 2.02
2024 1.18
2023 1.31
2022 6.23

About CERo Therapeutics Financial Statements

CERo Therapeutics investors use historical fundamental indicators, such as CERo Therapeutics' Cash Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in CERo Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash Per Share 1.18  2.02 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for CERo Stock Analysis

When running CERo Therapeutics' price analysis, check to measure CERo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CERo Therapeutics is operating at the current time. Most of CERo Therapeutics' value examination focuses on studying past and present price action to predict the probability of CERo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CERo Therapeutics' price. Additionally, you may evaluate how the addition of CERo Therapeutics to your portfolios can decrease your overall portfolio volatility.